Loading quotes...

Forecast

Buy	4
Hold	4
Sell	0

News Go to news feed

Acer pauses release of oversized Nitro Blaze 11 handheld amid tariffs and manufacturing shifts

Acer’s 11‑inch Nitro Blaze gaming handheld, unveiled at CES 2025 with a planned Q2 release, has been delayed indefinitely. Company says US tariffs forced it to prioritize core laptop lines and seek manufacturing outside China, leaving the Blaze and smaller siblings without imminent launch plans. Acer confirms the devices are on the back burner with no current timeline for release. » More on theverge.com
Acer unveils Swift 16 AI with world’s largest haptic trackpad and stylus

Acer introduced refreshed Swift, Nitro and Predator laptops at CES 2026, led by the Swift 16 AI featuring a 175.5 x 109.7 mm haptic trackpad and included stylus, optional OLED and Intel Panther Lake chips up to Core Ultra X9 388H. Other updates include Swift Go and Swift Edge models with Panther Lake chips (Swift Go 16 AI to use AMD) and contextual media controls on mechanical trackpads. Gaming lineup adds Nitro V 16S AI and Predator Helios Neo 16S AI with Nvidia RTX 50-series GPUs and Panther Lake CPUs. Acer gave release windows but no pricing: Swift 16 AI and Swift Go 16 AI expected in Q1 2026, other Swifts in Q2, and the gaming models in Q3. » More on theverge.com
Acer unveils multiple laptops and monitors ahead of IFA 2025 in Berlin

Ahead of IFA 2025 in Berlin, Acer announced a wide range of new products including the Chromebook Plus Spin 514 with MediaTek Kompanio Ultra 910, the ultra-light Swift Air 16, refreshed Predator gaming laptops and several stylish monitors including Amadana-branded models. Coverage also highlights other IFA product reveals across the show such as LG’s smart-home AI ambitions, JBL’s PartyBox 720 speaker, Dolby Vision 2 updates, Ooni’s AI pizza oven and teaser products from Dangbei. The Verge will provide live coverage and hands-on impressions from the IFA show floor between September 5–9, 2025. » More on theverge.com

Financials

In the last year, Acer Therapeutics had revenue of €0 and net profit of -€24.46m

(EUR)	2022	YoY
Revenue	0	100.00%
Gross profit	0	100.00%
Net profit	-24.46m	80.92%
EBITDA	-24.3m	74.07%

Fundamentals

Metric	Value
Market capitalization	€0
52-week high/low	€4.06 - €0.49
Dividends	No
Beta	0.44
P/E ratio	-0.37
PEG ratio	0.01
P/B ratio	-0.62
P/S ratio	0.00

Company profile

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.